Karine Pozo
Associate Director, Program Management Immatics Gmbh
At Immatics, Dr. Karine Pozo leads strategic planning and execution of clinical and research programs in PRAME-directed TCR T-cell therapies. Immatics is a clinical-stage biotechnology company and the global leader in the precision targeting of PRAME. PRAME is a target expressed in more than 50 cancers and Immatics has the broadest PRAME franchise with the most PRAME indications and modalities. Karine coordinates cross-functional teams to advance TCR T-cell therapy initiatives through clinical development, supporting Immatics’ mission to make a meaningful impact on the lives of patients with cancer. Karine holds a Ph.D. in Molecular Neurosciences from the University of London.
Seminars
Thursday 17th September 2026
Clinical Activity of IMA203CD8, a PRAMEDirected TCR T-Cell Therapy in Solid Tumors
2:10 pm
- Targeting of PRAME across tumor types with IMA203CD8 leveraging both CD8+ and CD4+ T cells
- Sharing promising clinical results from a PRAME-directed TCR T-cell therapy including proof-of concept in ovarian cancer
- Discussing opportunities for tumor-agnostic development across a broad spectrum of PRAME expression levels
